A Phase 2a Study to Evaluate the Safety and Efficacy of Cannabidiol Only as Maintenance Therapy and Steroid Sparing in Patients With Stable Autoimmune Hepatitis

Summary

Subjects with stable autoimmune hepatitis disease currently being administered corticosteroids with or without azathioprine (AZA) treatment will be be treated with Cannabidiol instead of standard of care treatment with corticosteroids

Timeline

Start

2019-02-07

Primary completion

2020-03-01

Completion

2020-03-01

Outcome

Outcome not reported

Stopped (Enrollment): “low recruitment”

Drugs

Indications